US$ 22.52
gip/glp-1 drugs The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Compounded Tirz GLP-1/GIP Online |
Description
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

C., Edmondson, S., Feeney, W

Candeias E, Sebastio I, Cardoso S, Carvalho C, Santos MS, Oliveira CR, et al

SM has received grants from Boehringer Ingelheim and Novo Nordisk, personal fees for advisory boards from Aventis, Boehringer Ingelheim, MSD and Novo Nordisk, and personal fees for lectures from Novo Nordisk

270.The National Weight Control Registry 2025
Li J, Liu X, Fang Q, Ding M, Li C
